Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?

摘要: The central importance of angiogenesis and our understanding how new blood vessels are formed have led to the development novel antiangiogenic therapies. Although number agents in has grown exponentially, only one phase III trial breast cancer been completed. In that study addition bevacizumab capecitabine did not extend progression-free survival patients with refractory disease as compared monotherapy. Early enthusiasm for therapy must give way clinical reality. Our challenge now is exploit better activity seen early studies.